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ABSTRACT 
The subject of this paper is the relationship between glucose- 
6-phosphate dehydrogenase (G6PD) deficiency and bacterial infection. 
The relevant literature is reviewed in two parts. First, major bio¬ 
chemical and clinical aspects of G6PD deficiency are discussed. The 
second part covers neutrophil function and dysfunction; leukocyte G6PD 
and the implications of its deficiency are placed within the context 
of other neutrophil disorders. A hospitalized Iranian population 
comprised our study group. When we compared the rates of G6PD deficiency 
in infected and non-infected patients, the difference reached statistical 
significance under certain circumstances (.05 > p > .01). Our data 
also showed the G6PD deficient infected patients to be significantly 
younger than the G6PD normal infected patients (.005 > p > .001). This 
is consistent with the hypothesis that G6PD deficient patients, once 
infected, have a more severe clinical course. We conclude that there 
are significant interactions between G6PD deficiency and bacterial 
infection, although their exact nature remains to be defined. Mechanisms 
which would explain an association between these two conditions are 
discussed. 
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I 
Definitions and History 
Glucose-6-phosphate dehydrogenase (G6PD), the first enzyme in 
the pentose phosphate pathway, catalyzes the conversion of glucose-6- 
phosphate to 6-phosphogluconolactone while reducing NADP to NADPH 
[Figure l]. The major practical importance of G6PD lies in its role 
in the red blood cell, where its deficiency can cause hemolytic anemia. 
Most commonly, the anemia is episodic and is related to one of a number 
of agents, but occasionally a chronic hemolytic anemia occurs. Although 
the former entity has been known for thousands of years, it was only 
recently that the link between G6PD deficiency and hemolytic anemia was 
established. In 1926, plasmoquin, an 8-amirioquinoline compound, was 
first used in treating syphilitics who had been inoculated with malaria; 
shortly thereafter, a series of reports appeared describing hemolytic 
anemia with administration of the drug [1]. Little progress was made 
in determining the etiology of the condition until 1950, when investi¬ 
gators received a new research tool in the form of primaquine, a compound 
related to but therapeutically more effective than plasmoquin. In 1954 
Dern et al. [2], utilizing cross-transfusions between normal and 
primaquine-sensitive individuals, demonstrated that the basic abnormality 
was in the red blood cell. Other investigators found that the hemolytic 




least some metabolic processes were known to decrease with aging, 
attention was directed towards a metabolic disorder [1], In 1965, 
Carson and his collaborators [3] reported a decreased G6PD level in 
the erythrocytes of affected individuals. 
Mechanisms of Hemolysis 
Although it was soon generally accepted that the G6PD deficiency 
and hemolytic anemia were related, detailed understanding of the hemo¬ 
lytic mechanism was and still is lacking. An outline of events as they 
are known requires a brief digression into certain aspects of erythrocyte 
biochemistry. 
As mentioned before, G6PD is one of the enzymes of the hexose 
monophosphate shunt (HMP) [Figure l]. This pathway is very important 
to the red blood cell, even though it metabolizes a much smaller quantity 
of glucose than the Embden-Meyerhof pathway. The reduction of NADP to 
NADPH and the production of the nucleotide precursor ribose-5-phosphate 
take place via the HMP. The latter can also be formed by other means; 
in contrast, NADPH in red cells is supplied entirely by the HMS. A 
source of NADPH is critical because it acts as the coenzyme for the 
conversion of oxidized glutathione (GSSG) to reduced glutathione (GSI1) . 
The GSH prevents the oxidation of sulfhydryl groups of proteins such 
as hemoglobin, usually because GSH itself is instead oxidized to GSSG. 
In cases where the oxidant is GSH acts by reducing the H,,G^ to 
H^O [4], A second important role of NADPH is to provide electrons for 
reduction and cleavage of GSK-hemoglobin complexes, which would otherwise 
be liable to precipitate. 
■ f ■ • . 
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It is believed that infections, fava beans, and other stimuli 
induce hemolysis by causing the production of various oxidizing substances 
such as or ot^er unstable radicals. Drugs themselves can also 
have oxidizing capacity. In the normal person, these substances can 
be handled by the production of NADPH from the HMS, but G6PD deficiency 
blocks this pathway. Consequently, the erythrocyte proteins, including 
hemoglobin, are not protected from oxidation. Oxidized hemoglobin can 
denature and precipitate as Heinz bodies, and by binding to and damaging 
the cell membranes, the Heinz bodies increase cell susceptibility to 
removal by the reticuloendothelial system [1,5]. 
Baehner £t al. [6] have made a more specific proposal regarding 
the mechanism of hemolysis during infection; they suggest that HpC^ 
produced by phagocytizing leukocytes could serve as a partial source 
of the oxidant stress. Their hypothesis was supported by experiments 
in which phagocytizing leukocytes caused a fall in GSII in neighboring 
G6PD deficient red blood cells, a result associated with increased 
destruction of these cells in the liver and spleen. The effect was 
not present with normal erythrocytes, nor with separation of the G6PD 
deficient cells from the leukocytes. Pyrimidine aglycons have been 
implicated as the offending agent in favism [7], and naturally occurring 
substances such as ascorbate, pyruvate, and cysteine in "spontaneous" 
hemolysis [5]. 
G6PD Variants 
During the course of these and other investigations, it became 
clear that G6PD deficiency varied enormously biochemically and clinically. 
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Over 80 variants have now been described in the 100 million or so people 
with the condition [8], and doubtless more remain to be found. Only 
a few of the major variants will be discussed here; complete compilations 
are available in the literature [9,30]. 
The normal G6PI) enzyme, known as type B, has a molecular weight 
of 190,000 to 240,000 and has 3 to 6 similar or identical subunits, 
although the functioning enzyme is probably dimeric [1]. The biochemical 
properties, including substrate affinity, thermostability, optimal pH, 
and electrophoretic characteristics, are well known [Table 1], One of 
the most common variants, called type A because it migrates faster than 
type B, is present in approximately 30 percent of American black males 
[5]. With the use of trypsin digests, it was found to differ from type B 
by only a single amino acid [11]. Type A has normal activity and so has 
little clinical importance, in contrast to Type A (which receives its 
name because it migrates wit3t Type A, but has decreased activity). 
About 11 percent of American black males have Type A [5] and the gene 
exists in varying frequencies throughout Africa. The catalytic activity 
of each A enzyme molecule, is close to normal, but there is a fall in 
the total number of molecules [1], and the decrease in activity between 
young and old cells is more marked than in normal cells [12,13]. Overall, 
the activity in the blood is usually 5-15 percent of normal [5]; very 
rarely, activity can be absent [14]. Affected individuals are generally 
asymptomatic except under conditions of stress, such as with certain 
drugs or infection [Table 2]. Because G6PD activity is low only in 
older cells, the hemolysis tends to be mild and self-limited; a typical 
.. 0 ' 
. 
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time course involves an onset 1 to 3 days after the inciting agent has 
been introduced, with recovery beginning in A to 6 days [5]. 
A more severe form of G6PD deficiency is found in the Mediterranean 
area, including Sardinia, Italy, Greece, Iran, Rumania, Israel, and 
perhaps some areas in the Far East [15]. It is possible that G6PD 
Mediterranean, as it is known, represents a heterogeneous group [11,16, 
17,18] but the major biochemical characteristics listed in Table 1 are 
constant. The frequency of the gene ranges from less than 0.1 percent 
in Northern Europe to greater than 50 percent of Kurdish Jewish males 
[5]. The quantity of enzyme is reduced in very young red blood cells, 
and their catalytic efficacy is also lower [1]. Because all erythrocytes 
are affected, the G6PD activity of whole blood tends to be less than 
1 percent, and the hemolytic episodes are often more severe and not 
self-limiting. The list of precipitating agents is similar to, but not 
identical with, that for G6PD A ; for example, chloramphenicol causes 
hemolysis in G6PD Mediterranean but not G6PD A [Table 2]. Fava beans, 
which can lead to an extremely rapid and severe hemolysis, also appear 
to affect mainly Caucasians [8]. Another factor may also be involved, 
since only some G6PD Mediterranean patients are affected by the fava 
beans. 
A host of other G6PD variants have been described, ranging from 
G6PD Canton, similar in its properties to G6PD Mediterranean [15], G6PD 
Oklahoma, with a tremendous deterioration in activity with aging [19] 
and G6PD Hektoen, with increased activity [5]. The clinical manifesta¬ 
tions depend on the characteristics of the enzyme; patients can be 
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asymptomatic, have mild or severe disease resembling that described 
above, or rarely, have a chronic nonspherocytic anemia. Seen with some 
of the rarer types of G6PD deficiency, as well as occasionally in G6PD 
Mediterranean, the degree of shortened erythrocyte lifespan is generally 
mild [5], 
Leukocyte G6PD 
G6PD deficiency is not necessarily limited to the red blood cells 
and articles have appeared describing decreased levels in leukocytes, 
lens tissue, kidney, adrenal tissue, platelets, saliva, liver and other 
tissues [1]; most of these studies were in Caucasians [8,20]. A 
complete analysis of these reports is not feasible here, and only the 
leukocyte levels will be discussed in some detail. While most people 
believe that the leukocyte and erythrocyte enzymes are the same [1], 
some investigators have claimed differences [1,19] and the issue has 
not been definitively settled. One published report even showed separate 
inheritance of the two defects, but the measurement techniques described 
are open to question [21]. Moreover, the findings have not been con¬ 
firmed by other researchers. In any case, several different studies 
have demonstrated lowered leukocyte levels in association with some 
types of erythrocyte G6PD deficiency. Marks and Gross [12] reported 
that Caucasian, but not black, males with severe erythrocyte G6PD 
deficiency (less than 4.5 standard deviations below control values) 
have a leukocyte G6PD level approximately one third that of controls. 
A similar study carried out by Ramot et jal. [22] showed leukocytes with 
25 percent of normal activity. Affected Chinese males have also been 
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found to have decreased leukocyte G6PD levels [23], The potential 
functional significance of lowered leukocyte G6PD levels to the anti¬ 
microbial activities of these cells will be discussed below. 
Mode of Inheritance 
The mode of inheritance of G6PD deficiency is well known to be 
X-linked. It was established by inheritance patterns, and with linkage 
studies of other traits such as color blindness and hemophilia A. 
The study of a patient with Turner's syndrome and fully expressed 
G6PD deficiency helped to rule out a sex-influenced process [7]. 
G6PD deficiency was, in fact, instrumental in confirmation of the 
Lyon hypothesis; Beutler et_ a_l. [24] studied females heterozygous for 
the trait and found two distinct populations of cells, rather than one 
with intermediate activity. It is a useful cell marker in other systems, 
for example the study of blood cell precursor development [25] and 
Down's syndrome [26]. 
G6PD Deficiency and Associated Conditions 
In the short time that it has been known, G6PD deficiency has 
been associated with a number of other pathological processes. Its 
relationship to bacterial infection is complex, and leukocyte G6PD 
levels may well play a role in host defenses. This subject will be 
addressed in the following two sections of this paper; here, only a 
brief review of specific associated conditions, infectious and non- 
infectious, is presented. 
One area of great controversy concerns whether G6PD deficiency 
4 
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might have a selective advantage in some circumstances. The fact that 
it is so common, and that the distribution to some extent parallels 
that of malaria, has led to the hypothesis that G6PD deficiency might 
confer a degree of protection against malaria. Support for this 
idea has been gathered in a series of experiments, most of which used 
G6PD A and Plasmodium falciparum; these experiments demonstrated 
decreased parasitization of the G6PD deficient red blood cells as 
compared to normal [27,28]. An explanation for this protection was 
proposed by Kosover [29]: the increased level of GSSG, a substance 
known to inhibit protein synthesis in rabbits, could act to retard 
parasite proliferation. These theories leave many points unexplained, 
including the fact that G6PD deficiency is so frequent and severe in 
areas where there is a fairly high selective disadvantage due to the 
popularity of fava beans. Huheey and Martin [30] suggested that 
favism may augment G6PD deficiency's protective effect against malaria, 
but this remains pure speculation. They also point out that G6PD 
Mediterranean may be particularly effective in combating P_. vivax, 
which is more important than P_. falciparum in Mediterranean areas. 
Their reasoning is that P. vivax has more exoerythrocytic stages than 
P_. falciparum, and in G6PD Mediterranean many body tissues, including 
the liver, are G6PD deficient. Finally, as Carson and Fischer [7] 
have noted, there are other diseases, such as plague, which have a 
similar distribution and might also have played a selective role. 
G6PD deficiency is a well known cause of neonatal jaundice, and 
in some parts of the world may be the most common one [19]. The process 
. 
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seems to affect Caucasian, Indian, and Oriental infants [8,31,32]. 
Valaes e_t al. [33] studied groups of Greek newborns, confirming the link 
between G6PD deficiency and neonatal jaundice while raising additional, 
complicating issues. They found evidence for another icterogenic factor 
which accentuated the jaundice in normal and deficient patients; they 
also found that the degree of hyperbilirubinemia and anemia were not 
always parallel, as one might expect in a hemolytic state. Recently, 
Meloni et al. [34], discovering that barbiturates were therapeutically 
effective, postulated that transiently impaired liver function could 
also be partly responsible for the jaundice. An increased incidence 
and severity of jaundice has also been noted in black and Caucasian 
hepatitis patients with G6PD deficiency [35,36,37], Doubtless this 
is partly due to hemolysis resulting from the oxidative stress of 
infection, but similar to neonatal jaundice, the evidence for hemolysis 
was not always entirely convincing, and other factors were believed 
to contribute. Jaundice has been associated with lobar pneumonia in 
African G6PD patients [38,39] and liver biopsies have shown changes 
consistent with cholestasis [40]. G6PD deficiency has been reported 
to predispose to typhoid in Ghana [41] and Thailand [42], but both 
studies could be questioned on grounds of bias in patient selection. 
A small study in India linked leprosy and G6PD deficiency [43], while 
TB was shown not to be related to G6PD deficiency in the Far East [44], 
Regarding non-infectious diseases, several investigators have 
produced population studies showing an inverse relationship between 
G6PD deficiency and malignancy [45,46,47,48], but the study and control 

10 
groups differ in a number of ways and many other etiologies are equally 
or more plausible. Beaconsfield [45] did have an interesting suggestion 
of why G6PD deficiency and cancer might be related: lack of G6PD by 
depressing the pentose phosphate pathway interferes with pentose sugar 
and nucleic acid production and impedes rapid growth. More recently, 
Eaton [49] noted that catalase inactivation stimulates the phosphate 
shunt and some investigators have found decreased liver catalase with 
hepatomas, reinforcing the idea that the pentose phosphate pathway may 
be an important limiting factor in neoplastic (and possibly malarial) 
processes. Other diseases described as being related to G6PD deficiency 
include thalassemia [50], cataracts [51], regional enteritis, and 
granulomatous colitis [52,53], but the data is tenuous. Finally, 
a considerable amount has been written on the relationship of Hemo¬ 
globin S and G6PD deficiency [54,55,56,57,58], While the controversy 
is not yet totally resolved, the prevailing opinion is that the genes 
are common in the same populations, but that the presence of one docs 
not appreciably alter the clinical course of the other. 

II 
NORMAL NEUTROPHIL FUNCTION [5,8,59] 
Production and Delivery 
Neutrophils, the chief phagocytic cells in the blood, make up 
the myeloid series together with eosinophils and basophils. The first 
morphologic stage in their development is the myeloblast; whether there 
are distinct myeloblasts for each of the three lines of the myeloid 
series is unknown. Morphologically, myeloblasts are characterized by 
large nuclei with two to five nucleoli and even, diffuse chromatin, 
while the small quantity of basophilic cytoplasm contains numerous 
mitochondria and no granules. Myeloblasts give rise to promyelocytes, 
which can be distinguished by the increasingly prominent endoplasmic 
reticulum and, more importantly, the appearance of primary, azurophilic 
granules. These are formed on the concave surface of the Golgi body 
and are rounded or elongated, with crystalline contents of lysosomal 
hydrolases, myeloperoxidase, cationic proteins and others. Secondary 
granules, which appear first in the myelocyte stage, are made on the 
convex surface of the Golgi body and are variable in shape. Their 
homogeneous appearing contents include alkaline phosphatase and lacto- 
ferrin. This type of secondary granule is unique to neutrophils, and 
the myelocyte is thus the first stage at which differentiation of cell 
11 
./* I i 1 • 
12 
lines can be made. Metamyelocytes have clearly indented nuclei lacking 
nucleoli, and moderately dense, sometimes clumped nuclear chromatin. 
The endoplasmic reticulum is much less prominent, as one would expect 
from the decrease in protein synthesis; under normal circumstances, 
metamyelocytes have probably lost their ability to divide and reproduce. 
The final two stages, the juvenile or band form and the mature poly¬ 
morphonuclear leukocyte are usually distinguished on the basis of their 
nuclei; the former has partial separation of the nuclear lobes, while 
in the latter there are only thread-like connections. The nuclei of 
mature cells have coarse, condensed chromatin, and the cytoplasm contains 
both types of granules. In accord with the fact that their main source 
of energy is glycolysis, there are large stores of glycogen but few 
mitochondria. Precise understanding of the regulation of the relative 
numbers of cells in various stages of development in the marrow, the 
intravascular pool (both circulating and marginated) and the tissues 
is lacking at present. Several granulopoietic agents have been described. 
Other factors which may regulate the number of cells in different body 
pools include physiologic cycling (possibly at several different inter¬ 
vals),' heat, exercise, emotional state, infection, and drugs [5,8]. 
The processes by which neutrophils are delivered to sites of 
inflammation are complex. For unknown reasons, capillary endothelium 
can change in such a way as to cause local granulocyte adherence 
followed by diapedesis through vessel walls [60], This tends to occur 
in injured areas, and the white cells are further drawn to inflamed 
regions by two kinds of substances: cytotoxins, which act directly, 
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including most Importantly by-products of complement activation, and 
cytotaxigens, which generate cytotaxins and include lysosomes, endo¬ 
toxins and immunologic complexes. These chemotactic factors do not 
increase the speed at which neutrophils move, but rather influence 
their direction [8]. It is known that while migrating, polymorpho¬ 
nuclear leukocytes develop a stiff rim of cytoplasm that contains actin 
polymers and glycogen particles, and that the ability to assemble micro¬ 
tubules is integral to responding with directed movement. Precise 
details of the events in migration are lacking, however. 
Phagocytosis: Recognition and Ingestion 
The susceptibility of many microbes to phagocytosis by neutrophils 
is enhanced by the process of opsonization. Both bacteria and poly¬ 
morphonuclear leukocytes, particularly immature forms, have a net 
surface charge which is negative and they therefore naturally tend to 
repel each other. Opsonins are traditionally defined as agents in 
serum which enhance the palatibility of particles [60]. They consist 
most importantly of heat-labile complement and heat stable antibody; 
specific receptors for the Fc. fragment of IgG and for C3b may exist in 
neutrophils. Specific IgG antibody, therefore, can bind and opsonize 
directly, although in most physiological situations complement is 
probably also activated. In contrast, IgM must act via complement 
fixation since it has no specific receptors. In the absence of antibody 
some bacteria themselves can activate the alternate complement pathway 
[60,61]. It is possible that different bacteria require fixation of 
different complement products [62], and under some circumstances organisms 
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can be taken up if there is a suitable surface against which they can 
be trapped, so-called "surface phagocytosis" [60], In order for the 
microbes to be ingested energy must be generated; as mentioned earlier, 
it is produced by glycolysis and oxygen is not required. This is 
probably advantageous, in view of the often anoxic inflammatory environ¬ 
ment. During the act of attachment the hyaline ectoplasm, the outer 
cytoplasmic rim, forms filopodia which surround the particle. With 
phagocytosis the cellular membrane surrounding the particle is internalized, 
forming a phagosome whose walls are comprised of former plasma membrane. 
Killing and Digestion 
During ingestion, lysosomes fuse with the phagosomal membrane 
and discharge their contents into the vacuole; most likely the secondary 
granules fuse shortly before the primary. This process is known as 
lysosomal degranulation and the enzymes released mediate the oxygen 
independent microbicidal system. They have a variety of partially 
understood effects; for example, the hydrolases are believed to digest 
the bacteria and to prevent bacterial multiplication, lactoferrin binds 
iron, a necessary growth factor, and myeloperoxidase has a complicated 
bactericidal role to be discussed later. Many of the strongly cationic 
granular proteins also seem to be microbicidal, perhaps by binding to 
acidic groups on the target organisms and in some way preventing growth. 
In addition, lactate accumulation and carbonic acid production result 
in an acid environment in the phagocytic vacuole; this has an adverse 




In the normal sequence of events phagocytosis is followed by 
a burst of metabolic activity; the actual stimulus has been shown to 
be mediated by surface perturbation [63,64]. The oxidation of glucose 
via the hexose monophosphate shunt increases as does oxygen consumption, 
setting into motion the oxygen dependent bacterial mechanisms. Recent 
evidence has shown that the first event in the formation of bactericidal 
compounds is a one electron reduction, of oxygen, resulting in superoxide 
anions, 0^ [65] [Figure 2], Not only is this agent intrinsically 
toxic, but it is an intermediate in the production of more such agents, 
^2^2 an<^ ^ the following reactions: 
(1) 2 0 • + 2H+ - H20? + 02 [66] 
(2) 02" + H202 -> 02 + Oil” + OH* [67] 
These substances, together with other unstable intermediates (for 
example singlet oxygen) comprise the myeloperoxidase independent, 
oxygen dependent bactericidal system. In the myeloperoxidase mediated 
system, hydrogen peroxide and an oxidizable cofactor, usually a halide, 
are required. The hydrogen peroxide, provided by bacterial or leukocyte 
metabolism, forms a complex with the iron of the heme moiety delivered 
into the phagocytic vacuole by degranulation; this complex in turn forms 
antimicrobial substances by oxidizing the cofactor. The nature and 
mode of actions of these substances are known to vary with the cofactor 
but are not completely understood [67], Figure 2 demonstrates some of 
the postulated interrelationships between phagocytosis-stimulated oxygen 
consumption, superoxide and peroxide formation and pathways for their 
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utilization in intact granulocytes. 
NEUTROPHIL ABNORMALITIES 
Disorders of Production and Delivery [5,8] 
Neutrophil disorders can best be divided into those of production 
and delivery, recognition and ingestion, and killing and digestion. 
Granulocytopenia, here defined as a reduction in circulating neutrophils, 
can result from reduced granulopoiesis, impaired release from the marrow, 
or decreased cell survival. A variety of drugs and infections can 
produce granulocytopenia by any one or a combination of these mechanisms, 
and several hereditary syndromes exist which have been tentatively 
classified. Infantile genetic agranulocytosis is among the examples 
of reduced granulopoiesis. Inherited in an autosomal recessive pattern, 
the findings consist of marked neutropenia, moderate anemia, frequent 
severe infections and a bone marrow revealing maturation arrest at the 
myelocyte stage. Two forms of an autosomal dominant familial neutropenia 
exist: one in which there is moderate neutropenia, no clinical diffi¬ 
culties, and an essentially normal bone marrow, and a more severe type 
in which infections are very common and most of the granulocytes do not 
mature beyond myelocytes. An interesting report exists of two brothers 
with periodontal and throat infections whose granulocytes showed this 
maturation defect and whose plasma inhibited the differentiation of 
normal cells. A number of cases of cyclic neutropenia, involving 
approximately three week cycles of neutropenia and mild infection, have 
been described. It seems likely that the problem is one of mild marrow 
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failure and feedback mechanisms. Schwachman's syndrome consists of 
pancreatic insufficiency and neutropenia, the infections varying with 
the degree of the latter. Neutropenia can also be associated with 
immunoglobulin abnormalities, usually in the pediatric age group. 
Bone marrow examination again reveals myelocyte arrest, and the patients 
are subject to numerous infections. In another type of neutropenia, 
the entire granulocyte series is hypoplastic, in contrast to the normal 
erythropoiesis and thrombocytopoiesis. Classically, chronic dermatologic 
infections are apparent. Myelophthisis is another cause of reduced 
granulopoiesis, although pancytopenia is more likely to develop. 
Chronic benign neutropenia is believed to result from increased 
peripheral destruction, and therefore belongs in the second category. 
The bone marrow reveals bands but few mature forms, and most patients 
have a moderately increased incidence of pyogenic infection. A similar 
but clinically less severe form exists in adults. Two kinds of transient 
neonatal neutropenia have been reported, one in which the mothers them¬ 
selves also were neutropenic and one, similar to red cell incompatibility, 
in which the mothers presumably had become sensitized to the fetus' 
leukocytes and transmitted agglutinins. Cases of leukocyte autoantibody 
and neutropenia often occur with connective tissue diseases, particularly 
systemic lupus erythematosis. The opposite of granulocytopenia, 
granulocytosis, can result from any one of a large number of conditions, 
for instance infections, inflammatory disorders, tumor, treatment with 
certain drugs (e.g., corticosteroids), emotional stimuli, and metabolic 
and hemotologic diseases. Hereditary forms, although extremely rare. 
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also exist. A number of mechanisms including increased production of 
cells in the marrow and release into the circulation shifts from mar- 
ginating to circulating pools or decreased exit from the circulation 
can be invoked to explain granulocytosis in these states. 
The Pelger-Huet anomaly is an example of another type of 
production disorder, that of a predominantly morphologic abnormality. 
It is a dominant condition which, in the heterozygous state, causes 
leukocyte nuclei to have a decreased number of lobes, so called 
"pince-nez" nuclei. That, together with the persistence of nucleoli 
and the coarse nuclear chromatin, are suggestive of an abnormality of 
nuclear maturation. While these cells function normally, the homo¬ 
zygous state is felt to be lethal. Interestingly, similar cells are 
seen in pseudo or acquired Pelger-Huet anomaly, which is associated 
with various malignancies, metabolic diseases, infections, and so forth. 
A generally benign condition with hypersegmented nuclei is also known, 
and can mimic the morphology seen in vitamin or folate deficiency. 
The May-Hegglin anomaly is a disease in which the granulocytes have 
basophilic inclusions but apparently function normally; the platelets, 
however, also have inclusions and sometimes abnormal bleeding occurs. 
Alder-Reilly leukocytes, associated with polysaccharide disorders such 
as Hunter’s and Hurler's syndromes, also contain giant granules but 
function normally. The Chediak-Higashi syndrome and other granule 
abnormalities will be discussed as disorders of phagocytosis as they 
have important functional significance. 
The well-named lazy leukocyte syndrome exemplifies impaired 
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neutrophil delivery; interestingly, both random movement and chemotaxis 
are impaired. This presumably causes the peripheral neutropenia and 
poor response to infection. Other tests of phagocytosis, bactericidal 
capacity, and humoral and cellular immunity are normal. The two children 
with the disease had presented with recurrent stomatitis, otitis, 
gingivitis, and low grade fevers [68]. 
The constellation of findings known as Job's syndrome was first 
described in two red haired, fair skinned girls with recurrent cold 
staphylococcal abscesses [69], Laboratory tests on these patients 
[69,70] revealed no abnormalities, although two similar patients 
reportedly failed to reduce nitroblue tetrazolium [71] (see below for 
discussion of this test). More recently, however, a paper has appeared 
in which the leukocytes were found to have defective chemotaxis and 
extremely high IgE levels. Random migration, phagocytosis and bac¬ 
tericidal activity against staphylococcus and JE. coli were normal. 
The suggestion was made that patients with Job's syndrome lack the 
ability to develop an early inflammatory response and are therefore 
extremely susceptible to staphylococcus, the most common bacterium on 
the skin. Some experimental support is available in animals, in whom 
it has been shown that infection will be suppressed only if an appropriate 
inflammatory response takes place in two to four hours. The authors' 
explanation for the lack of classic signs of inflammation associated 
with the abscesses was intriguing, although pure speculation: the 
leukocytes, spending more time in the systemic circulation and there 
being exposed to an increased histamine level, might therefore release 
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fewer inflammatory mediators in local sites [72]. Clark et aJL. [73] 
reported a case of an eleven year old girl with recurrent pyogenic 
and mucocutaneous Candida infections. Examination revealed normal 
production of chemotactic factors, but impaired migration; cellular 
immunity also was abnormal. One possible etiology of abnormal mobility 
was suggested by a brief report of an infant with bacterial skin and 
visceral infections, neutropenia, and decreased migration. Electron 
microscopy showed a defect of contractile proteins comprising cellular 
microfilaments, perhaps of actin polymers [74], Other factors may also 
be involved; for example, cirrhotic patients have impaired chemotaxis 
associated with both a serum inhibitor and a deficit of complement [75]. 
Disorders of Recognition and Ingestion [59] 
Several examples of recognition and ingestion defects are known. 
Defective opsonization may be partly responsible for the increased 
susceptibility of newborns to infection. IgM, which may be useful in 
the opsonization of gram negative organisms, is not transported across 
the placenta and lack of it may account for some of this [76]. Levels 
of both IgG [77] and complement [78] are related to birth weight, which 
may lead to additional difficulties for low birth weight infants. It 
has been shown that serum from sickle cell patients does not enhance 
pneumococcal phagocytosis as well as normal serum, and there is some 
evidence that this is due to a defect in the alternate complement 
pathway [79]. An infant with eczema, diarrhea, and recurrent infections 
with staphylococci and gram negative organisms was reported to have 
a dysfunction of C5. Although no decrease in C5 could be found, the 
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defect v/as repaired by the addition of purified C5 [62,80]. Defects 
of other complement components, resulting in a wide range of clinical 
findings, have also been reported [81]. Another type of syndrome is 
termed tuftsin deficiency. Tuftsin is a tetrapeptide covalently bound 
to leukokinin, a leukophilic gamma globulin. It is cleaved off by 
an enzyme called leukokininase and is thought to act directly on the 
phagocyte, not the opsonized target. Tuftsin is probably synthesized 
in the spleen, as it is absent in splenectomized individuals. Four 
patients with rash, lymphadenopathy, and pulmonary disease, caused by 
staphylococcus, streptococcus, Candida, and perhaps other organisms, 
have been reported. They were found to have an inactive tuftsin mutant, 
and clinically they responded to the administration of gamma globulin 
[82]. 
Disorders of Killing and Digestion [59] (See Figure 2) 
Among the causes of impaired killing and digestion are disorders 
which affect the neutrophil granules. Chediak-Higashi syndrome appears 
to result from abnormal granule formation in cells throughout the body, 
but the primary defect is not known. Histochemically, the granules 
contain normal constituents for the cell line in which they appear; in 
neutrophils, they are primary granules. Patients with the disease have 
light coloring, due to the decreased number of melanin granules, and 
an increased incidence of infection. A study by Root et al. [83] showed 
that Chediak-Higashi neutrophils have defective bactericidal defences 
against catalase positive and catalase negative organisms, secondary 
to a delay and a decrease in the transfer of granule enzymes. Phagocytosis 
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as well as the metabolic response to phagocytosis were found to be 
normal, but the authors note that neutropenia and an impaired chemotactic 
response have also been demonstrated in this disease. A second type 
of primary granule abnormality is myeloperoxidase (MPO) deficiency. 
As described above, MPO is required for part of the oxygen-dependent 
bactericidal system of leukocytes. It may also help regulate hexose 
monophosphate shunt (HMP) metabolism, and help protect neutrophils from 
the toxic effects of [84], In the presence of azide and cyanide, 
which inhibit MPO by forming complexes with the iron in the heme moiety, 
killing of Lactobacillus acidophilus, Staphylococcus aureus, and Candida 
t.ropicalis is impaired [85]. MPO deficiency, which appears to be an 
autosomal recessive trait, has been described in five patients. Of 
these, only one had an increased susceptibility to infection; he had 
disseminated candidiasis, but it should be noted that the patient had 
diabetes mellitus as well. Study of the neutrophils revealed normal 
phagocytosis, decreased killing of serratia and S. aureus, and absent 
killing of Candida. HowTever, the fact that the man did not present 
until middle age, and that the other cases are clinically wTell, speaks 
against MPO being an essential part of defense mechanisms [84]. Perhaps 
the polymorphonuclear leukocytes have a great overkill capacity, or 
perhaps they are able to compensate with an increase in their non MPO 
dependent bactericidal mechanisms. The latter suggestion is supported 
by Klebanoff’s [85] demonstration that MPO deficient leukocytes are 
more efficientthan azide treated normal leukocytes in killing ingested 
bacteria. It is interesting that one case of anomalous specific, 
. 
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secondary granules has been reported. A 14 year old boy with recurrent 
staphylococcal infections of the skin and respiratory tract had neutro¬ 
phils with bilobed nuclei and decreased bactericidal activity against 
staphylococcus. A complete lack of leukocyte alkaline phosphatase was 
found and may have been related in some way to the killing disorder 
[86], although it should be noted that the low-leukocyte alkaline 
phosphatase in chronic myelogenous leukemia is not associated specifi¬ 
cally with impaired microbicidal activity. 
A second category of defective bactericidal mechanisms is that 
in which the neutrophils do not have the appropriate metabolic response 
after phagocytosis: they do not increase their oxygen consumption and 
glucose metabolism to produce . While all aerobic bacteria produce 
^2^2 ^ ^eir own metabolic pathways, some contain catalase to break it 
down. Catalase negative organisms, however, provide a source of 
which is apparently sufficient to allow normal bactericidal mechanisms 
to proceed; hence, patients with this sort of abnormality are more 
prone to infection with catalase positive bacteria only [87]. The. 
large number of reactions involved in hydrogen peroxide production and 
catabolism implies that any one of a number of different enzymatic 
defects could produce this picture (see Figure 2). In chronic granu¬ 
lomatous disease, of childhood (CGD), perhaps the best known example 
of this type of disease, recent work has shown a deficiency of NADPH 
oxidase activity [87], The function of this enzyme is to generate the 
highly reactive reduction product of oxygen superoxide. Hydrogen 
peroxide is then formed by a dismutation reaction in which one molecule 
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of is oxidized and the other reduced producing anc^ ^2* 
defect in CGD is probably a failure of activation rather than an 
absence of the enzyme [88], Much of the earlier confusion may stem 
from the fact this deficiency can be detected only in phagocytizing 
cells, whereas resting cells appear normal. The failure in pentose 
shunt activity is believed to be secondary to the failure of 
production. Classically, these patients are males whose disease is 
inherited in an X-linked recessive pattern. Catalase positive bacteria 
which are ingested, but usually not killed, are transported to the 
reticuloendothelial system, where they gradually are released and 
rephagocytized by macrophages which may be similarly defective [89]. 
The granuloma formation which follows can be compared to that of 
tuberculosis and brucellosis, where live organisms also survive intra- 
cellularlv for long periods of time [90]. The typical clinical picture 
is one of widespread reticuloendothelial involvement (lymphadenopathy, 
hepatomegaly, splenomegaly) as well as numerous infections (pustulur 
dermatitis, conjunctivitis, osteomyelitis, subcutaneous abscesses, 
pneumonia). Laboratory workup should include a nitroblue tetrazolium 
(NBT) test as part of an evaluation of immune competence. Normal 
leukocytes reduce this soluble yellow dye to an insoluble purple 
formazan which is easily visualized [91]. CGD leukocytes, for reasons 
probably related to decreased superoxide anion production [66], are 
incapable of reducing the dye. In a few instances, patients who appear 
to have CGD have been found to lack glutathione peroxidase rather than 
NADPH oxidase. This has been noted mainly in females [92], although 
• ; 
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one case of a Japanese male has been recorded [93]. CGD, therefore, 
may not be a single disease entity. 
Glucose-6-phosphate dehydrogenase appears to be intimately 
involved in hydrogen peroxide formation and catabolism. Through the 
activity of G6PD, the NADPII needed to reduce oxygen to superoxide is 
produced. Hydrogen peroxide is then derived from by dismutation 
as shown in Figure 2. On this basis, one might predict that a lack of 
leukocyte G6PD would cause a lack of hydrogen peroxide formation and 
affect cellular metabolism and function in a way mimicking CGD. A 
comparison of the two types of cells has been made, and it was found 
[94] that leukocyte G6PD levels less than 5 percent of normal resulted 
in defective killing of catalase positive bacteria. Similar to CGD 
leukocytes, there is no post phagocytic respiratory burst with 
production, and there is failure of NTjT reduction. Both will reduce 
NBT if cells are disrupted and NADH or NADPH is added. The addition 
of methylene blue (MB) differentiates the two types of cells by the 
following reactions: 
(1) NADH/NADPH + MB dlaPhora5e , NAD/NADP + MBH 
(2) MBH + 02 -S°S£°ma.tic„_., m + h2o2 
MB added to CGD cells will stimulate normal pentose shunt activity and 
improve microbicidal activity [94], G6PD deficient cells which have 
decreased levels of NADH and NADPH will exhibit no such response on 
exposure to MB. Further study of the G6PD deficient cells revealed 





with G6PD activity of 20-50 percent of normal had no functional defects; 
as mentioned before, only at 1-5 percent levels were bactericidal 
abnormalities detected [94], 
One group of investigators [95] postulated that G6PD deficiency 
might be responsible for some cases of classic CGD; they observed an 
increased rate of decay of G6PD activity in three male CGD patients. 
A 16 month old girl with CGD, defined by a compatible clinical history 
and failure to reduce NBT, was found to have a white cell G6PD level 
approximately half of normal. Of note is the fact that her parents 
were first cousins [96]. While the clinical significance of these 
reports can be questioned, at least two patients with complete absence 
of leukocyte G6PD and impaired microbicidal activity are known. One 
was a middle-aged Caucasian female with hemolytic anemia and fatal 
E. coli sepsis [97], Studies of her leukocytes, whose G6PD activity 
was completely nondetectable, revealed normal bacterial ingestion, 
normal destruction of S_. faecalis (catalase-negative), and abnormal 
destruction of S_. aureus, _E. coli and S_. marcesens (catalase-positive). 
As one would predict, an NBT test revealed no reduction. Measurements 
of leukocyte NADH and NADPH oxidase were not different from controls. 
The patient’s post-transfusion erythrocyte G6PD level was 50 percent 
of normal; four brothers, three sisters and one son all had normal red 
and white cell G6PD and no increased incidence of infection. Genetically, 
it is possible that the patient was homozygous for an autosomal recessive 
gene which in some way affects G6PD activity, or that she was hetero¬ 
zygous for the X-linked G6PD gene. In the latter case, one must invoke 
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the Lyon hypothesis and postulate that most of the cells with the 
normal gene were inactivated [97]. A family was described by Gray 
et al. [98] in which the male propositus had chronic nonspherocytic 
hemolytic anemia, pneumonia, and recurrent granulomatous staphylococcal 
infections since puberty. Leukocyte function abnormalities were similar 
to, although less marked than the previously described patient. Roth 
erythrocyte and leukocyte G6PB were nondetectable, even by immunologic 
studies. Of two brothers with the. same G6PD finding, one had had a 
single episode of cervical lymph adenitis and one had no history of 
unusual infections. The father had low normal and the mother inter¬ 
mediate levels of red and white cell G6PD. Metabolic activity post 
phagocytosis (glucose oxidation, formate oxidation and iodination) was 
nearly identical in the propositus and his brother with lymphadenitis; 
these measurements were not made in the symptom-free brother, although 
his leukocytes had not reduced NBT. Conceivably two X-linked genetic 
defects, G6PD deficiency and a form of CGD, are present in this family, 
but it seems more likely that the G6PD deficiency is responsible for 
the clinical symptomatology. 
A disorder termed lipochrome histiocytosis bears some resemblance 
to the disorders of bactericidal function just described and some feel 
it is a type of CGD. Three sisters with the syndrome have been reported, 
of whom one failed to reduce NBT. All had impaired post phagocytic 
respiration and HMP activity. Other clinical and laboratory features 
included pulmonary infiltrates, splenomegaly, rheumatoid arthritis, 
increased susceptibility to infection, hypergammaglobulinemia and 
. 
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defective staphylococcal destruction; pathologically, the histiocytes 
had lipochrome pigmentation. Unlike CGD, there was no evidence of 
granuloma formation, in spite of the bactericidal defect presumably 
resulting in prolonged intracellular survival of bacteria [99,100]. 
Miscellaneous Disorders 
A number of other, for the most part, poorly understood syndromes 
exist which have in common defective killing of staphylococci; some may 
turn out to be the same as one of the above. A female patient with 
recurrent staphylococcal infections had normal chemotaxis, phagocytosis, 
and NET reduction, but an unstable leukocyte pyruvate kinase. Other 
leukocyte enzymes, as well as red blood cell and lymphocyte pyruvate 
kinase, were normal [101]. Another young woman with staphylococcal 
facial infections, pneumonia and bacteremia was found to have normal 
leukocyte bactericidal activity against E_. coli but defective activity 
with staphylococcus. The fact that the parents were related and that 
there was a rather high number of infant deaths in the- family pedigree 
led the author to suggest an autosomal recessive disorder, but its 
nature is not known [102]. A girl with fatal phycomycosis whose 
leukocytes showed decreased bactericidal capacity against staphylococcus 
and a negative NBT test might have had a form of CGD, but her sex and 
benign clinical course until the age of 13 is extremely atypical [103]. 
A family in which two, possibly three siblings of both sexes suffered 
from oral, respiratory and skin infections has been reported; unlike 
in CGD, the neutrophils exhibited a normal respiratory burst with 
phagocytosis of IgG coated particles, but not with plain latex particles 
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[104], Finally, it should be pointed out that not all of these syndromes 
are necessarily related to neutrophil dysfunction. A potential example 
is a male with repeated staphylococcal infections culminating in death 
at age 19. Although his immunoglobulins were normal, he was found to 
lack specific antibodies to the staphylococcal F and S antigens of 
leukocidin. The hypothesis was made that the patient may have become 
tolerant of staphylococcal antigens during the second trimester of 
pregnancy when his mother had impetigo [105]. Such speculation is 
interesting but wild, and is perhaps an indication of the great amount 




In the preceding section neutrophil function and dysfunction 
were discussed, and the role of G6PD in bactericidal mechanisms reviewed 
in the context of other abnormalities. Leukocytes with a G6PD level 
less than 5 percent of normal were shown to have defective killing of 
catalase positive bacteria; several cases of individuals with G6PD 
deficient leukocytes and increased infection susceptibility were cited. 
Other ways in which G6PD deficiency might be related to infection have 
been proposed, for example, via the hemolysis which so often occurs. 
Kaye and his collaborators [106,107] have shown that acute hemolysis 
in mice lowers resistance to S.. typhimurium, E. coli, and JS. aureus, 
but not to D. pneumoniae. They theorized that macrophages may become 
temporarily overloaded with erythrocyte products, and may be unable to 
sustain their usual bacterial defenses as well. The possibility also 
exists that free hemoglobin itself can increase infection susceptibility, 
by providing an easily accessible source of iron for invading microbes 
[108]. In addition, there is some evidence that G6PD deficiency is 
associated with pneumococcal and salmonella infections, suggesting a 
defect in opsonization'similar to that in sickle cell disease [A2]. 
That G6PD deficiency can adversely affect host defense against 




established as described above, but whether it also plays a role in 
large populations is not known. In order to answer this question, we 
decided to study a population in which severe G6PD deficiency and 
bacterial infections were both common, to see whether infected patients 
had a higher rate of G6PD deficiency. Although it was not feasible 
for us to measure leukocyte G6PD levels in addition to those in the 
erythrocytes, we chose a Caucasian population in which deficiency of 
the latter is known to be associated with deficiency of the former. 
All bacterial infections were included, and where possible, subgroups 
were analyzed, to allow for the different mechanisms that may be 
operative. 
Materials and Methods 
(a) Patient selection 
The project was carried out in Shiraz, Iran at Nemazee and Saadi 
Hospitals, two teaching hospitals affiliated with Pahlavi University 
Medical School. All subjects were Iranian males, and all except one 
were inpatients at one of these hospitals. Approximately three times 
per week charts were reviewed of all adult patients in Nemazee Hospital, 
and from the medical, orthopedic and neurosurgical wards in Saadi 
Hospital. During the last month of the three month period, pediatric 
charts were also reviewed. Patient data were gathered from the charts 
and when necessary, from responsible medical personnel. The data 
collected included age, place of origin, history of present illness, 
past medical history, family history, physical examination findings, 
laboratory data, procedures performed, therapy received, and hospital 
'■ 
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course. All male inpatients with bacterial infections and no known 
predisposing reason to infection other than possible G6PD deficiency 
were studied as the infected group. Infections were diagnosed by one 
or more of the following methods: cultures, titers, biopsies, x-rays, 
diagnostic taps, and antibiotic response. In cases where the etiologic 
agent was definitively established by cultures, titers, or biopsies, 
the patient was categorized as Class I. In other cases the presence 
of a bacterial infection was well established by a combination of 
clinical symptoms, x-rays, examination of body fluids, biopsies and 
antibiotic response, but proof of the etiologic agent was not obtained 
and the patient was categorized as Class II. Patients in whom an 
etiologic agent was highly suspected, but not proven (for example, 
a chest x-ray with cavitary lesions in a person with clinical signs 
of tuberculosis) wrere also placed in the latter category. The one 
outpatient in the infected group was seen at Nemazee Outpatient Clinic, 
brucellosis titers were diagnostic, and it was elected to give him 
antibiotics at home rather than in the hospital. Those patients free 
of diseases known to be associated with infection or G6PD deficiency 
were selected as control "A". As far as possible, all individuals with 
systemic diseases were avoided. Thus, to isolate G6PD deficiency as 
a potential cause for bacterial infections, patients who had the 
following conditions or treatments were, excluded from the infected and 
the major control groups: steroid therapy, malignancy, diabetes 
mellitus, cirrhosis, chronic renal or cardiac failure, sickle cell 
anemia, Cooley’s anemia, malaria, hydatid cyst, open trauma, opium 
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^buse, viral infections, tetanus, vasculitis or renal stones, and those 
in whom no diagnosis could be made. Most patients identified with these 
conditions were not tested, since these disorders in and of themselves 
can predispose to secondary bacterial infections. In some situations 
G6PD testing was performed on individuals with these conditions before 
all clinical data was available, and they serve as control "E". This 
provided us with two control groups; control "A" is a group selected 
for a lack of predisposing factors for bacterial infection, and control 
"B" a group with a variety of potentially predisposing factors to 
infection, or syndromes which mimicked bacterial infections in some 
of their features. 
(b) Assay 
Measurement of erythrocyte G6PD activity was carried out as 
follows: for each assay approximately 5 cc. of blood was drawn into 
a syringe, transferred immediately to a Vacutainer tube containing EDTA, 
and mixed well. Bloods were refrigerated at 4°C within 15 minutes and 
were tested within three days with the semiquantitative method developed 
by Sigma (Technical Bulletin No. 400). Kit instructions were followed 
exactly, including appropriate compensation for the degree of anemia 
present. In this assay, erythrocytes are lysed by water to release 
G6PD, This solution is then added to glucose-6-phosphate and NADP in 
the presence of phenazine methosulfate, an electron carrier and 
dicblorophenol indophenol, a blue dye. The NADPH formed during the 
oxidation of glucose-6-phosphate to 6-phosphogIuconate reduces the dye 
to a colorless form, and the rate of the reaction can be followed 
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visually. The tubes are observed for a six hour period. For a 
minority of patients the quantitative test for G6PD activity performed 
in the Nemazee Hospital Laboratory (Brilliant Cresyl Blue Reduction, 
Dade, Miami, California) was used. In these cases, only samples with 
0% activity were considered deficient. 
(c) Grouping of data and statistical analysis 
Statistical significance of differences in rates of G6PD defi¬ 
ciency were determined by the chi-square method of 'analysis. Infected 
patients were compared with control "A" and control "A" plus control "B" 
No separate comparisons with control nB': were made, because of the 
small number of subjects. Subgroups of patients matched exactly for 
age and origin were analyzed in a similar way. Those infected patients 
in whom an etiologic agent was established were divided according to 
whether the agent was catalase positive or negative. The catalase 
positive group was compared with controls, but the catalase negative 
group was too small to permit statistical analysis. The unpaired "t11 
test was used to analyze the mean age difference between the G6PD normal 
and the G6PD deficient infected groups. With both the chi-square and 
the unpaired "t" test, p < .05 is considered statistically significant. 
Results 
(a) Assay validity 
Before conducting the studies in Iran assays were run at Yale 
University School of Medicine using blood samples tested quantitatively 
by the Yale-New Haven Hospital laboratories. The age of the samples 
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ranged from two hours to eleven days. Samples of all ages with normal 
G6PD activity decolorized within one hour, and samples with 10 percent 
activity decolorized in two to two and a half hours, consistent with 
data obtained by Sigma. 
In Iran, an effort was made to study all infected patients as 
soon as possible after admission, usually within a few days. It was 
not always feasible to carry out the assays when no medications were 
being given; however, a complete list of drugs that each patient was 
receiving was compiled, and no agents that might have affected the assay 
were present in the study group. Fourteen of our seventeen abnormal 
samples had not decolorized at 6 hours, indicating very severe defi¬ 
ciency. Two of the remaining three took 3 hours but when repeated 
took 4 hours or more, and the third took 4^ hours but could not be 
repeated. Of the 14 that took more than 6 hours, 5 were randomly 
repeated and all confirmed the original result; in 2 cases the assay 
was performed within 2 hours of the time the blood was drawn. Three 
of the normal assays were repeated and confirmed. 
(b) Patient characteristics 
The demographic characteristics of all patients are presented in 
Table 3. The average age of the 55 infected patients was 31 years; the 
G6PD normal group differed substantially from the G6PT) deficient grouD, 
34 years compared to 22. This difference was statistically significant 
(.005 > p > .001). There were 65 control "A" patients, with an average 
age of 34 years, and 33 control "B" patients, with an average age of 
38 years. In these two groups there was no marked difference between 
. 
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G6PD normal and G6PD deficient patients. The distribution between 
those from villages and from major cities was relatively even, although 
a somewhat greater proportion of the control "A" group came from the 
cities. Of the city patients, a total of seven came from places other 
than Shiraz (three infected patients and three control "B,: patients, 
one each from Yazd, Teheran, and Mashad, and one control "A" patient 
from Yazd). It seems reasonable to assume that villagers are less 
likely to travel, and that therefore an even smaller percentage is 
from outside the Shiraz area. 
The criteria by which infections were established are listed 
in Table 4, and the diagnoses themselves in Table 5. Tables 6a and 6b 
contain the diagnoses of control "A" and control "B" respectively. 
Some of the patients had a history of a disease other than that for 
which they were admitted to the hospital. Of the infected patients, 
three had a past history of typhoid (the present illnesses were two 
with pneumonia and one with osteomyelitis), one had psoriasis (shigel¬ 
losis), and one had hypertension (meningitis). Of the control "A” 
patients, one had had typhoid (snake bite), one had had malaria (upper 
gastrointestinal tract bleed), and one had an ulcer (low back pain); 
of control "B:l patients, one had rheumatoid arthritis (and was on 
steroid therapy) and one had had smallpox (diagnosis of present illness 
not made). 
The results of the G6PD assays are in Table 7. Twenty two 
percent of the infected patients were G6PD deficient, compared to 
twelve percent of control "A" and six percent of control "B" (Table 7a). 

37 
Tables 7b, 7c, and 7d show the rates of G6PD deficiency in three sub¬ 
groups, one with matched ages, one with matched origins (villagers 
only), and one selected on the basis of whether the etiologic agent 
was catalase positive or catalase negative. Matching for age wTas 
important from two aspects: older patients might have a lower frequency 
of G6PD deficiency if the gene causes an increase in mortality rates 
and older patients have a naturally higher rate of infection for a 
variety of reasons. Matching for origin was important to account for 
genetic differences in rates of G6PD deficiency, and genetic and environ¬ 
mental differences in rates of infection. We looked at whether infections 
were caused by catalase positive or catalase negative organisms, because 
of the previously cited work showing the G6PD deficient leukocytes may 
be similar to CGD leukocytes in demonstrating impaired killing of cata¬ 
lase positive organisms [92], 
For Tables 7a, 7b, and 7c the differences in rates of G6PD defi¬ 
ciency between the infected group and control "A11 were analyzed by the 
chi-square method, and in all cases the differences were found not to 
be statistically significant (p > .10). Comparisons were also made 
between each infected group and control "A" plus control "B". The 
results are as follows: 
Table Patient Group X ^ £ 
7a all 3.86 .05 > p > .01 
7b age-matched 3.67 .10 > P > .05 
7c origin-matched 1.79 P ~ .10 
Thus, when controls "A" and "B" together are considered as the control 
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group, the differences in rates of G6PD deficiency reached statistical 
significance. No separate comparisons with control "B" were made, 
owing to the small number of subjects. For Table 7d, the catalase 
positive group was compared with all control "A" patients (Table 7a), 
and with all control "A" patients plus control "B" patients (Table 7a). 
The differences were not statistically significant (p > .10). The 
catalase negative group had no G6PD deficiency, but statistical analysis 
was not carried out because of the small size of the group. 
Mortality data was collected but is incomplete because it was 
not possible to follow patients remaining in hospital after termination 
of the study. As far as is known, none of the 12 G6PD deficient infected 
patients and 2 of the 43 G6PD normal infected patients expired. There 
was no mortality in the control ’’A" group of 65 patients; in control "B11, 
one of the 2 G6PD deficient and 3 of the 31 G6PD normal patients failed, 
to survive. 
Discussion 
The frequency of G6PD deficiency in Iran has been studied by 
a number of other investigators (see Table 8), and our results are in 
rough agreement. We did not have enough geographic distribution to 
confirm or refute Beaconsfield1s [110] finding of a higher incidence 
in previously malaria-infested areas. 
Although the rates of G6PD deficiency were greater in infected 
than in control groups, the differences were not significant when the 
control group was matched as closely as possible for age, origin, and 
underlying diseases. When we included a secondary control group with 
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a variety of conditions that were not present in the infected groups, 
the differences reached significance (p as low as .05 > p > .01, in 
patients matched exactly for age). However, the secondary control 
group included patients whose susceptibility to infection might have 
been increased due to disease (other than G6PD deficiency) or therapy, 
thus it was not strictly comparable with the infected patient group. 
One might expect an artificially low rate of G6PD deficiency in control 
"B" as the combination of G6PD deficiency and infection could lead to 
an increased mortality. The same bias could occur if patients with 
G6PD deficiency are less liable to develop the types of disorders 
present in control "3". Either of these possibilities would explain 
why the differences in rate of G6PD deficiency between the infected 
and control groups increase when the secondary control group is included. 
Some studies have shown that G6PD deficient individuals are more 
susceptible only to catalase positive organisms (see previous section), 
but our comparison of the group infected with catalase positive 
organisms and the controls showed no statistically significant differ¬ 
ences in the frequency of G6PD deficiency. Although the rate of G6PD 
deficiency in the catalase negative group was zero, the number of cases 
was too small to permit meaningful statistical analysis. Neither did 
we have enough subjects with any one disease to analyze separately, 
and so we cannot make a definite statement on this issue. However, 
the G6PD deficient patients did seem to have a disproportionate share 
of staphylococcal septicemia, pneumonia, and brucellosis. We also 
compared the demographic characteristics of the G6PD deficient infected 
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group with the G6PD normal infected group. The average age of the 
former was 22 years, and the latter 34 years (difference significant 
at the .005 > p > .001 level). One interpretation of this observation 
is that the combination of G6PD deficiency and infection leads to 
hospitalization at an earlier age than infection alone. This is 
consistent with the hypothesis that G6PD deficient patients, once 
infected, have a more severe clinical course. Data on mortality rates 
would be useful in further testing of this hypothesis, but our data 
are insufficient for this purpose. 
It is important to point out what we feel are some potential 
weaknesses in our study. The number of patients sampled was relatively 
small, and conceivably some of the observed trends might become signifi¬ 
cant only in a large population study. Lack of optimal facilities and 
culturing techniques prevented us from establishing every diagnosis of 
infectious disease by culture, and sampling error might have been involved 
in those that were. It was not possible for us to fully document 
previous antibiotic therapy, and this would be important in altering 
the course of infectious diseases. We were not able to measure leuko¬ 
cyte G6PD levels, which would have made our study more precise. Exact 
data on leukocyte G6PD activity would be particularly relevant in 
establishing the clinical significance of defective pentose phosphate 
metabolism in the cells. Finally, the method of patient selection might 
be faulted in several ways. Specifically, ongoing hemolysis caused by 
infection or its treatment can lead to hospital admissions. By concen¬ 
trating only on patients with infections severe enough to result in 

hospitalization, a true picture of a population's susceptibility to 
infection is not obtained. Rather, one has only an estimate of the 
prevalence of serious infections, and this estimate does not differ¬ 
entiate between infections made more severe by G6PD deficiency (with 
or without hemolysis) and the reverse. Close monitoring of hemolytic 
parameters before hospitalization would be required to determine whether 
this is a source of bias, as well as perhaps producing information cn 
the relationship of hemolysis and infection; it would also provide a 
more accurate index of the incidence of infection in normal and G6PD 
deficient subjects. By selecting mainly adult patients, we automatically 
minimized the chances of detecting very serious effects of G6PD defi¬ 
ciency on host resistance, which could result in early mortality. Borne 
of the information we attempted to collect may not have been reliable 
and complete. Thorough medical records were not always available and 
some relevant data may have been deleted including precise statements 
concerning ethnic background, nutritional status, and means of referral. 
Another population study of the relationship of G6PD deficiency 
and infection has been published by Lampe et al. [42], They compared 
rates of G6PL) deficiency in hospitalized Thai children with S. typhi, 
H. influenza b, pneumococcus, staphylococcus, and tuberculous infections 
with outpatient controls. Taking only male patients, their data show 
a difference in rate of G6PD deficiency between the infected group and 
the controls approaching significance (p - .05), a finding rather similar 
to ours. Their criteria for diagnosis of infectious disease were more 




and it is not clear how well the patients and controls were matched 
for exact age and origin. Furthermore, like our study, their method 
of patient selection precludes an estimate of the relative incidence 
rates for infection in normal and G6PD deficient subjects. 
Thus, while we can offer no final conclusions regarding the 
relationship of G6PD deficiency and bacterial infections, a reasonable 
interpretation of data from these studies is that the two conditions 
do have meaningful interactions. This statement is justified by our 
data showing the G6PD deficient infected group to be significantly 
younger than the G6PD normal infected group, indicating the adverse 
effect of having both G6PD deficiency and infection. Although a rise 
in the rate of G6PD deficiency in an infected hospital population versus 
a non-infected population was demonstrated both by Lampe and ourselves, 
this rise approaches statistical significance only under certain cir¬ 
cumstances. Therefore, whether it is real remains to be evaluated. 
There are several mechanisms which would explain an association 
between G6PD deficiency and bacterial infection. First, as we have 
suggested above, the oxidant stress of infection or its treatment may 
lead to hemolysis and a weakening of host defenses against infection 
as well as hospitalization. Second, if the leukocyte G6PD level is 
less than 5 percent of normal, bactericidal activity against catalase 
positive organisms can be impaired. On the basis of published information, 
it is more likely that this occurs on an individual basis, rather than 
in all patients with reduced leukocyte G6FD. A thorough prospective 
analysis of large groups Is required to pick up the more subtle 
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influences which might increase infection rates as well as severity. 
In such a study, the importance of other factors, such as hemolysis 
and abnormal opsonization, could be evaluated. This project would be 
potentially useful in providing additional knowledge of host defense 
mechanisms, as well as having clinical importance to the millio-ns of 
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TABLE 2 (from Reference 1) 
COMPOUNDS KNOWN TO HAVE INDUCED HEMOLYSIS OF 













































* Slightly hemolytic in Negroes, or only in very large doses, 
t Hemolytic in Caucasians, but not in Negroes. 
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DIAGNOSTIC CRITERIA IN INFECTED PATIENTS 
DIAGNOSIS CRITERION FOR DIAGNOSIS 
Pneumococcus Culture 
Staphylococcal sepsis Culture 






A. israelii abscess Biopsy 








CXR and response to antibiotics 
LP and response to antibiotics 
X-ray or biopsy 
CXR 
Response to antibiotics 
Pus and air in CSF 
Pus in pleural fluid 




LIST OF INFECTED PATIENTS BY DIAGNOSIS 
Diagnosis 































^In 2 cases, one of which was G6PD deficient, the etiologic agent 
was determined by culture to be pneumococcus. 
2 
In 1 case, which was G6PD normal, the etiologic agent was deter¬ 




LIST OF CONTROL "A" PATIENTS BY DIAGNOSIS 
DIAGNOSIS 





Low back pain 
Hernia 




















LIST OF CONTROL "B" PATIENTS BY DIAGNOSIS 
DIAGNOSIS 



































^Underlying causes (malignancy, hydatid cyst, TB) not ruled out. 
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